🔴 Telix Pharmaceuticals is trading 7.13% down today on profit-taking after Pixclara FDA approval

Telix Pharmaceuticals is trading 7.13% down at $11.91, apparently reflecting profit-taking after the September 14 FDA approval of Pixclara.

• Shares rose 8.91% to $12.83 on September 15.
• Pixclara is Telix’s first FDA-approved FET-PET imaging drug for glioma, triggering a sharp approval-driven rally.
• Broader markets are mixed; company-specific post-catalyst selling is the most likely explanation.